Treatment Patterns and Outcomes of Young Female Early Breast Cancer in Taiwan

Overview

Journal J Breast Cancer

Date 2025 Mar 6

PMID 40047089

Authors

Chi-Cheng Huang

Ling-Ming Tseng

Affiliations

Soon will be listed here.

Abstract

Young female early breast cancer (≤ 40 years) treatment presents unique challenges due to its aggressive features. Using data from the Taiwan Cancer Registry (2007-2017), this study investigated its clinical characteristics, treatment patterns, and prognostic factors. The proportion of young female breast cancer declined from 12% to 8% during the study period. Triple-negative (TN) breast cancer was more prevalent in younger patients, while hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative subtypes increased with age. Stages II and III were observed more frequently in older patients, whereas extremely young patients (20-29 years) exhibited compromised overall and recurrence-free survival. Subtype analysis revealed worse outcomes for TN and hormone receptor-negative/human epidermal growth factor receptor 2-positive (HER2+) cases. Treatment patterns showed that targeted therapy was more commonly administered to younger patients with HER2+, while endocrine therapy was used less frequently for HR+ cases, reflecting tolerability and treatment compliance challenges. Future research should focus on optimizing therapeutic strategies and addressing long-term survivorship to enhance care for young women with breast cancer.

References

Partridge A, Hughes M, Warner E, Ottesen R, Wong Y, Edge S . Subtype-Dependent Relationship Between Young Age at Diagnosis and Breast Cancer Survival. J Clin Oncol. 2016; 34(27):3308-14. DOI: 10.1200/JCO.2015.65.8013. View

Chiang C, Chen Y, Chen C, You S, Lai M . Cancer trends in Taiwan. Jpn J Clin Oncol. 2010; 40(10):897-904. DOI: 10.1093/jjco/hyq057. View

Shen Y, Chang C, Hsu C, Cheng C, Chiu C, Cheng A . Significant difference in the trends of female breast cancer incidence between Taiwanese and Caucasian Americans: implications from age-period-cohort analysis. Cancer Epidemiol Biomarkers Prev. 2005; 14(8):1986-90. DOI: 10.1158/1055-9965.EPI-04-0932. View

Vaz-Luis I, Francis P, Di Meglio A, Stearns V . Challenges in Adjuvant Therapy for Premenopausal Women Diagnosed With Luminal Breast Cancers. Am Soc Clin Oncol Educ Book. 2021; 41:1-15. DOI: 10.1200/EDBK_320595. View

Koivisto H, Nevala A, Miettinen J, Pitkaniemi J, Malila N, Heikkinen S . Relative risk of second malignant neoplasms highest among young adult cancer patients - a population-based registry study in Finland. Acta Oncol. 2024; 63:418-425. PMC: 11332513. DOI: 10.2340/1651-226X.2024.34138. View

Liao Y, Zhang J, Hsu Y, Hong M, Lee L . Age-Specific Breast Density Changes in Taiwanese Women: A Cross-Sectional Study. Int J Environ Res Public Health. 2020; 17(9). PMC: 7246480. DOI: 10.3390/ijerph17093186. View

Caswell-Jin J, Sun L, Munoz D, Lu Y, Li Y, Huang H . Analysis of Breast Cancer Mortality in the US-1975 to 2019. JAMA. 2024; 331(3):233-241. PMC: 10792466. DOI: 10.1001/jama.2023.25881. View

Alhaidary A, Al-Qudimat A, Arabi H, Al-Zoubi R . Imaging Patterns in Breast Cancer for Women Under 40 Years: A Descriptive Cohort Study. J Epidemiol Glob Health. 2024; 14(1):63-71. PMC: 11043463. DOI: 10.1007/s44197-023-00169-2. View

Benitez Fuentes J, Morgan E, de Luna Aguilar A, Mafra A, Shah R, Giusti F . Global Stage Distribution of Breast Cancer at Diagnosis: A Systematic Review and Meta-Analysis. JAMA Oncol. 2023; 10(1):71-78. PMC: 10636649. DOI: 10.1001/jamaoncol.2023.4837. View

10.

Lin C, Yap Y, Lee K, Im S, Naito Y, Yeo W . Contrasting Epidemiology and Clinicopathology of Female Breast Cancer in Asians vs the US Population. J Natl Cancer Inst. 2019; 111(12):1298-1306. PMC: 6910158. DOI: 10.1093/jnci/djz090. View

11.

Hanson S, Lei X, Roubaud M, DeSnyder S, Caudle A, Shaitelman S . Long-term Quality of Life in Patients With Breast Cancer After Breast Conservation vs Mastectomy and Reconstruction. JAMA Surg. 2022; 157(6):e220631. PMC: 9008558. DOI: 10.1001/jamasurg.2022.0631. View

12.

Schmid P, Cortes J, Pusztai L, McArthur H, Kummel S, Bergh J . Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med. 2020; 382(9):810-821. DOI: 10.1056/NEJMoa1910549. View

13.

Kang D, Park S, Kim H, Lee J, Han J, Kim S . Comprehensive Young Age Breast Cancer registry from clinical, genomics, and patient-reported outcomes measured with 15 years follow-up: the CHARM cohort profile. Breast Cancer. 2024; 31(3):467-475. DOI: 10.1007/s12282-024-01559-5. View

14.

Chen Y, Su S, Jhuang J, Chiang C, Yang Y, Wu C . Forecast of a future leveling of the incidence trends of female breast cancer in Taiwan: an age-period-cohort analysis. Sci Rep. 2022; 12(1):12481. PMC: 9304355. DOI: 10.1038/s41598-022-16056-y. View

15.

Lin C, Chen Y, Chiang C, Lu Y, Kuo K, Huang C . The emerging epidemic of estrogen-related cancers in young women in a developing Asian country. Int J Cancer. 2011; 130(11):2629-37. DOI: 10.1002/ijc.26249. View

16.

Tung N, Lin N, Kidd J, Allen B, Singh N, Wenstrup R . Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer. J Clin Oncol. 2016; 34(13):1460-8. PMC: 4872307. DOI: 10.1200/JCO.2015.65.0747. View

17.

Xu S, Murtagh S, Han Y, Wan F, Toriola A . Breast Cancer Incidence Among US Women Aged 20 to 49 Years by Race, Stage, and Hormone Receptor Status. JAMA Netw Open. 2024; 7(1):e2353331. PMC: 10818222. DOI: 10.1001/jamanetworkopen.2023.53331. View

18.

Yu S, Cai X, Wang X, Lin X, Cai S . Disease burden of breast cancer and risk factors in Europe 44 countries, 1990-2019: findings of the global burden of disease study 2019. Front Endocrinol (Lausanne). 2024; 15:1405204. PMC: 11153740. DOI: 10.3389/fendo.2024.1405204. View

19.

Dominici L, Hu J, Zheng Y, Kim H, King T, Ruddy K . Association of Local Therapy With Quality-of-Life Outcomes in Young Women With Breast Cancer. JAMA Surg. 2021; 156(10):e213758. PMC: 8411359. DOI: 10.1001/jamasurg.2021.3758. View

20.

Cathcart-Rake E, Ruddy K, Bleyer A, Johnson R . Breast Cancer in Adolescent and Young Adult Women Under the Age of 40 Years. JCO Oncol Pract. 2021; 17(6):305-313. DOI: 10.1200/OP.20.00793. View